188 related articles for article (PubMed ID: 15821951)
1. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans.
Agorastos A; Demiralay C; Stiedl O; Muhtz C; Wiedemann K; Kellner M
Int Clin Psychopharmacol; 2016 May; 31(3):176-8. PubMed ID: 26752621
[TBL] [Abstract][Full Text] [Related]
3. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
Demiralay C; Jahn H; Kellner M; Yassouridis A; Wiedemann K
World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
[TBL] [Abstract][Full Text] [Related]
4. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Dunayevich E; Erickson J; Levine L; Landbloom R; Schoepp DD; Tollefson GD
Neuropsychopharmacology; 2008 Jun; 33(7):1603-10. PubMed ID: 17712352
[TBL] [Abstract][Full Text] [Related]
6. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740.
Bergink V; Westenberg HG
Int Clin Psychopharmacol; 2005 Nov; 20(6):291-3. PubMed ID: 16192835
[TBL] [Abstract][Full Text] [Related]
8. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
[TBL] [Abstract][Full Text] [Related]
9. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
Demiralay C; Agorastos A; Yassouridis A; Jahn H; Wiedemann K; Kellner M
Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
[TBL] [Abstract][Full Text] [Related]
10. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats.
Shekhar A; Keim SR
Neuropharmacology; 2000 Apr; 39(7):1139-46. PubMed ID: 10760357
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R
Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826
[TBL] [Abstract][Full Text] [Related]
12. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
13. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
Kellner M; Yassouridis A; Jahn H; Wiedemann K
Psychopharmacology (Berl); 1997 Sep; 133(1):55-61. PubMed ID: 9335081
[TBL] [Abstract][Full Text] [Related]
14. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
15. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
Ströhle A; Holsboer F; Rupprecht R
Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
[TBL] [Abstract][Full Text] [Related]
16. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
17. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
Varma MV; Eriksson AH; Sawada G; Pak YA; Perkins EJ; Zimmerman CL
Drug Metab Dispos; 2009 Jan; 37(1):211-20. PubMed ID: 18838508
[TBL] [Abstract][Full Text] [Related]
18. Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
Goettel M; Fuertig R; Mack SR; Just S; Sharma V; Wunder A; den Boer J
CNS Drugs; 2023 Dec; 37(12):1099-1109. PubMed ID: 38019356
[TBL] [Abstract][Full Text] [Related]
19. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
Zwanzger P; Baghai TC; Schuele C; Ströhle A; Padberg F; Kathmann N; Schwarz M; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
Otte C; Moritz S; Yassouridis A; Koop M; Madrischewski AM; Wiedemann K; Kellner M
Neuropsychopharmacology; 2007 Jan; 32(1):232-8. PubMed ID: 17035932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
